THERAVECTYS is a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology.
TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs.
THERAVECTYS was founded in 2005 by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute. The company is based in Paris, Ile-de-France, France.
TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market.
TheraVectys is backed by investors including Bpifrance, Tethys BioScience, & Richard HENNESSY among others.